Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

14.28 -0.21 (-1.45%)
Streaming Delayed Price Updated: 3:30 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Why Biohaven Stock Crushed it on Monday ↗
The biotech was boosted by an analyst's initiation of coverage. 
Via The Motley Fool
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date. 
Via The Motley Fool
Topics Regulatory Compliance
Biohaven Ltd. (NYSE:BHVN) Posts Narrower-Than-Expected Q4 2025 Loss Amid Clinical Progress ↗
Via Chartmill
News headline image
XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗
Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo. 
Via Stocktwits
News headline image
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction ↗
SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy ↗
This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat cancers. 
Via The Motley Fool
Topics Regulatory Compliance
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Biohaven’s Phase II Depression Trial Falls Short, But Analysts Downplay Impact – Wall Street Looks Ahead To Epilepsy Data ↗
William Blair expected challenges with the depression study, given difficulties in executing trials and the prevalence of placebo effects. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Thursday's after hours session: top gainers and losers ↗
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Which stocks are moving after the closing bell on Wednesday? ↗
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts ↗
The company said that no reduction in depressive symptoms were observed in the BHV-7000 trial over six weeks as compared with placebo. 
Via Stocktwits
News headline image
Biohaven Insiders Bet $33 Million on a Turnaround ↗
Via MarketBeat
News headline image
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy? ↗
The Chief Accounting Officer added to his more than 85,000 shares held. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Teladoc Stock a Buy After Oracle Investment Management Upped Its Stake? ↗
The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock. 
Via The Motley Fool
News headline image
FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection ↗
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade. 
Via Benzinga
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 1%; Solid Power Shares Spike Higher ↗
 
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Surges 100 Points; McDonald's Posts Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug ↗
The company was nearing approval for a treatment for a rare, neurodegenerative disease. Then, the FDA spoke. 
Via Investor's Business Daily
Topics Earnings
News headline image
Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.